Logo

AstraZeneca Divests US Rights of Synagis & MEDI8897 to Sobi for Prevention of Serious Lower Respiratory Tract infection (LRTI)

Share this

AstraZeneca Divests US Rights of Synagis & MEDI8897 to Sobi for Prevention of Serious Lower Respiratory Tract infection (LRTI)

 Shots:

  • AstraZeneca to get $1.5B upfront ($1B in cash & 0.5B equity) plus $470M sales based milestones for Synagis. AZ has also sold US rights for its new candidate MEDI8897 to Sobi- for $175M milestone for BLA submission plus $110M development milestones & $60M non-contingent payment during 2019-2021
  • Sobi to get hold of the US rights for Synagis and MEDI8897 plus additional 8% equity in AZ (with terms & condition of not selling it before 12 mos. on closing of transaction). The profit and loss will be shared for AZ will continue to develop Synagis in collaboration with Sanofi Pasteur (division of Sanofi)
  • Synagis (palivizumab) is a novel mAb- inhibiting RSV F protein approved for RSV disease. MEDI8897 is a mAb- anti-RSV F indicated for prevention of LRTI caused by RSV

Ref: AstraZeneca| Image: Dennis Partners  

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions